This trial is testing a new drug called LGK974 to see if it is safe and effective in treating adults with cancer that has progressed despite standard therapy or for which no effective standard therapy exists.
1 Primary · 7 Secondary · Reporting Duration: 61 months
185 Total Participants · 2 Treatment Groups
Primary Treatment: LGK974 · No Placebo Group · Phase 1
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: